

**FLEURY S.A.**  
**Public Held Company**  
**Company Taxpayer's ID (CNPJ) 60.840.055/0001-31**  
**Company Registry (NIRE) 35.300.197.534**

**MATERIAL FACT**

Fleury S.A. ("Grupo Fleury" or "Company"), pursuant to paragraph 4 of article 157 of Law 6,404/76 and CVM Instruction 358/02, informs to its shareholders and the market in general that, on this date, its wholly-owned subsidiary, Fleury Centro de Procedimentos Médicos Avançados S.A. ("Fleury CPMA"), has closed the transaction to acquire 100% of the shares issued by Laboratório Pretti Ltda. ("Laboratório Pretti" or "Pretti"). On the same date, Fleury CPMA also closed the transaction to acquire 100% of the shares issued by Laboratório Bioclínico Ltda. ("Laboratório Bioclínico" or "Bioclínico").

The amounts agreed for both transactions have not changed in relation to what was informed in the Material Fact disclosed on June 1<sup>st</sup>, 2021.

None of the transactions is subject to the Company's shareholders' decision, nor will it give rise to the right to withdraw, in view of the terms of item 7.11 of Official Letter CVM /SEP/No. 01/2021

São Paulo, September 2nd, 2021

**JOSÉ ANTONIO DE ALMEIDA FILIPPO**

Chief Financial and Investor Relations Officer